Common Contracts
2 similar Purchase and Sale Agreement contracts by Agenus Inc, Ligand Pharmaceuticals Inc
PURCHASE AND SALE AGREEMENT dated as of May 6, 2024 by and among AGENUS INC., AGENUS ROYALTY FUND, LLC, AGENUS HOLDINGS 2024, LLC and LIGAND PHARMACEUTICALS INCORPORATEDPurchase and Sale Agreement • August 8th, 2024 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This PURCHASE AND SALE AGREEMENT (this “Agreement”), dated as of May 6, 2024, is by and between AGENUS, INC., a Delaware corporation (the “Company”), AGENUS Royalty FUND, LLC, a Delaware limited liability company (“Royalty Fund” and together with the Company, each a “Seller” and collectively, the “Sellers”), AGENUS HOLDINGS 2024, LLC, a Delaware limited liability company (“Product Sub”, and together with the Sellers, the “Seller Parties”), and LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation (the “Purchaser”).
PURCHASE AND SALE AGREEMENT dated as of May 6, 2024 by and among AGENUS INC., AGENUS ROYALTY FUND, LLC, AGENUS HOLDINGS 2024, LLC and LIGAND PHARMACEUTICALS INCORPORATEDPurchase and Sale Agreement • August 7th, 2024 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
This PURCHASE AND SALE AGREEMENT (this “Agreement”), dated as of May 6, 2024, is by and between AGENUS, INC., a Delaware corporation (the “Company”), AGENUS ROYALTY FUND, LLC, a Delaware limited liability company (“Royalty Fund” and together with the Company, each a “Seller” and collectively, the “Sellers”), AGENUS HOLDINGS 2024, LLC, a Delaware limited liability company (“Product Sub”, and together with the Sellers, the “Seller Parties”), and LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation (the “Purchaser”).
